Monitor for clinical trial initiation announcements in Q2 2026 for DMD and regulatory engagement updates for ALS in H2 2026. The Takeda partnership provides significant non-dilutive funding for elritercept development.
KROS drugs
KROS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $11.71entry
- T+1 · 9mo ago −3.50%α −2.19% · $11.30
- T+5 · 8mo ago −6.15%α −3.91% · $10.99
- T+20 · 8mo ago +2.48%α +6.27% · $12.00
- T+60 · 6mo ago −6.92%α −18.22% · $10.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics updated its corporate presentation for investor meetings, disclosing clinical trial timelines and preclinical data for its drug candidates rinvatercept and elritercept. The company expects to initiate a Phase 2 trial for Duchenne Muscular Dystrophy in Q2 2026 and engage regulators on an ALS trial in H2 2026. The presentation also highlights the $1.3 billion global licensing deal with Takeda for elritercept.
Key Facts
- Updated corporate presentation includes clinical development timelines for rinvatercept (DMD and ALS) and elritercept (MDS)
- Phase 2 DMD trial expected to commence in Q2 2026
- Regulatory engagement for ALS trial planned in H2 2026
- Takeda licensing agreement for elritercept includes $200M upfront payment and over $1.1B in potential milestones
- Presentation contains forward-looking statements about clinical trial design and timing
Financial Impact
No new financial data disclosed, but the Takeda deal represents $1.3B in potential value
Risk Factors
- Clinical trial timelines are forward-looking and subject to delay
- No efficacy data presented - trial outcomes remain uncertain
- Company has limited operating history and historical losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000021 |
| Document: corporatepresentationmar.htm | 0001664710-26-000021 |
| Document: 0001664710-26-000021-index-headers.html | 0001664710-26-000021 |
| Document: 0001664710-26-000021-index.html | 0001664710-26-000021 |
| Document: 0001664710-26-000021.txt | 0001664710-26-000021 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers